In 2022, Senator Breslin introduced S8193 and Assemblyman McDonald introduced A9250 which would prohibit the use of step therapy policies in dermatology, gastroenterology, hematology, neurology, rheumatology, oncology, and ophthalmology. Prohibiting step-therapy for these therapeutic categories will help prevent serious disease progression and encourage optimal health outcomes in patients that might otherwise be limited by step-therapy policies. Read the Fact Sheet here.
Last Updated on September 29, 2023 by Aimed Alliance
